Autres langues Adverum Biotechnologies, Inc.

Actions

ADVM

US00773U2078

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 01/05/2024			Varia. 5j.	Varia. 1 janv.
9,8 ^USD	+0,82 %		-3,83 %	+30,18 %

30/04	ADVERUM BIOTECHNOLOGIES, INC. : Opinion positive de HC Wainwright	ZM
29/04	ADVERUM BIOTECHNOLOGIES, INC. : Mizuho Securities réitère son opinion positive sur le titre	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting	25/04
Adverum Biotechnologies Files $200 Million Mixed Shelf	21/03
Adverum Biotechnologies: Q4 Earnings Snapshot	18/03
Adverum Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Adverum Biotechnologies, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	18/03
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates	18/03
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference	28/02
Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors	21/02
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	12/02
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD	08/02
Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD	08/02
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'	05/02
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing	05/02
Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors	05/02
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024	01/02
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer	29/01
Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee	29/01
Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society	07/12
Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference	28/11
Adverum Biotechnologies: Q3 Earnings Snapshot	09/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Adverum Biotechnologies, Inc.

Actions

ADVM

US00773U2078

Autres langues

Filtres